Glycosylation-related gene expression is linked to differentiation status in glioblastomas undifferentiated cells

Cancer Letters

Volumn 312, Issue 1, 2011, Pages 24-32

  Cheray, Mathilde ^a   Petit, Daniel ^b   Forestier, Lionel ^b   Karayan Tapon, Lucie ^c   Maftah, Abderrahman ^b   Jauberteau, Marie Odile ^a   Battu, Serge ^a   Gallet, François P ^b   Lalloué, Fabrice ^a  

^a UNIVERSITÉ DE LIMOGES   (France)

^b UNIVERSITY OF LIMOGES   (France)

^c UNIVERSITÉ DE POITIERS   (France)

Author keywords

Gene expression; Glioblastomas; Glycosylation; TLDA; Undifferentiated cells

Indexed keywords

MESSENGER RNA;

ADULT; ARTICLE; ATHL1 GENE; CANCER CELL; CANCER CELL CULTURE; CANCER TISSUE; CELL DIFFERENTIATION; CHI3L1 GENE; CONTROLLED STUDY; GAA GENE; GENE; GENE EXPRESSION; GLIOBLASTOMA; GLT25D2 GENE; GLYCOSYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; KLRC3 GENE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRUNE2 GENE; ST3GAL5 GENE; ST8SIA1 GENE; UPREGULATION;

BRAIN NEOPLASMS; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; GLYCOSYLATION; HUMANS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 80053311318     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.07.027     Document Type: Article

References (46)

1. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E., Mirimanoff R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352:987-996.
2. Lu C., Shervington A. Chemoresistance in gliomas. Mol. Cell. Biochem. 2008, 312:71-80.
3. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
4. Liu G., Yuan X., Zeng Z., Tunici P., Ng H., Abdulkadir I.R., Lu L., Irvin D., Black K.L., Yu J.S. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 2006, 5:67.
5. Bertrand J., Begaud-Grimaud G., Bessette B., Verdier M., Battu S., Jauberteau M.O. Cancer stem cells from human glioma cell line are resistant to Fas-induced apoptosis. Int. J. Oncol. 2009, 34:717-727.
6. Eyler C.E., Rich J.N. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J. Clin. Oncol. 2008, 26:2839-2845.
7. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
8. Sgambato A., Puglisi M.A., Errico F., Rafanelli F., Boninsegna A., Rettino A., Genovese G., Coco C., Gasbarrini A., Cittadini A. Post-translational modulation of CD133 expression during sodium butyrate-induced differentiation of HT29 human colon cancer cells: implications for its detection. J. Cell. Physiol. 2010, 224:234-241.
9. Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc. Natl. Acad. Sci. USA 2002, 99:10231-10233.
10. Zhao Y.Y., Takahashi M., Gu J.G., Miyoshi E., Matsumoto A., Kitazume S., Taniguchi N. Functional roles of N-glycans in cell signaling and cell adhesion in cancer. Cancer Sci. 2008, 99:1304-1310.
11. Reis C.A., Osorio H., Silva L., Gomes C., David L. Alterations in glycosylation as biomarkers for cancer detection. J. Clin. Pathol. 2010, 63:322-329.
12. Dawson G., Moskal J.R., Dawson S.A. Transfection of 2, 6 and 2, 3-sialyltransferase genes and GlcNAc-transferase genes into human glioma cell line U-373 MG affects glycoconjugate expression and enhances cell death. J. Neurochem. 2004, 89:1436-1444.
13. Bidlingmaier S., Zhu X., Liu B. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J. Mol. Med. 2008, 86:1025-1032.
14. Kemper K., Sprick M.R., de Bree M., Scopelliti A., Vermeulen L., Hoek M., Zeilstra J., Pals S.T., Mehmet H., Stassi G., Medema J.P. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res. 2010, 70:719-729.
15. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 2008, 8:755-768.
16. Osmond T.L., Broadley K.W., McConnell M.J. Glioblastoma cells negative for the anti-CD133 antibody AC133 express a truncated variant of the CD133 protein. Int. J. Mol. Med. 2010, 25:883-888.
17. Kroes R.A., Dawson G., Moskal J.R. Focused microarray analysis of glyco-gene expression in human glioblastomas. J. Neurochem. 2007, 103(Suppl. 1):14-24.
18. He J., Liu Y., Zhu T.S., Xie X., Costello M.A., Talsma C.E., Flack C.G., Crowley J.G., Dimeco F., Vescovi A.L., Fan X., Lubman D.M. Glycoproteomic analysis of glioblastoma stem cell differentiation. J. Proteome Res. 2011, 10:330-338.
19. Ermonval M., Petit D., Le Duc A., Kellermann O., Gallet P.F. Glycosylation-related genes are variably expressed depending on the differentiation state of a bioaminergic neuronal cell line: implication for the cellular prion protein. Glycoconjugate J. 2009, 26:477-493.
20. Reynolds B.A., Weiss S. Clonal and population analyses demonstrate that an EGF-responsive mammalian embryonic CNS precursor is a stem cell. Dev. Biol. 1996, 175:1-13.
21. Villalva C., Martin-Lanneree S., Cortes U., Dkhissi F., Wager M., Le Corf A., Tourani J.M., Dusanter-Fourt I., Turhan A.G., Karayan-Tapon L. STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastomas: a potential for targeted therapy?. Int. J. Cancer 2011, 128:826-838.
22. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., Scheithauer B.W., Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114(2007):97-109.
23. Lau K.S., Dennis J.W. N-Glycans in cancer progression. Glycobiology 2008, 18:750-760.
24. Shmelkov S.V., St Clair R., Lyden D., Rafii S. AC133/CD133/Prominin-1. Int. J. Biochem. Cell Biol. 2005, 37:715-719.
25. Contessa J.N., Bhojani M.S., Freeze H.H., Ross B.D., Rehemtulla A., Lawrence T.S. Molecular imaging of N-linked glycosylation suggests glycan biosynthesis is a novel target for cancer therapy. Clin. Cancer Res. 2010, 16:3205-3214.
26. Iwama E., Tsuchimoto D., Iyama T., Sakumi K., Nakagawara A., Takayama K., Nakanishi Y., Nakabeppu Y. Cancer-related PRUNE2 protein is associated with nucleotides and is highly expressed in mature nerve tissues. J. Mol. Neurosci. 2011.
27. Machida T., Fujita T., Ooo M.L., Ohira M., Isogai E., Mihara M., Hirato J., Tomotsune D., Hirata T., Fujimori M., Adachi W., Nakagawara A. Increased expression of proapoptotic BMCC1, a novel gene with the BNIP2 and Cdc42GAP homology (BCH) domain, is associated with favorable prognosis in human neuroblastomas. Oncogene 2006, 25:1931-1942.
28. Clarke R.A., Zhao Z., Guo A.Y., Roper K., Teng L., Fang Z.M., Samaratunga H., Lavin M.F., Gardiner R.A. New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progression. PLoS One 2009, 4:e4995.
29. Merzak A., Koochekpour S., Pilkington G.J. Adhesion of human glioma cell lines to fibronectin, laminin, vitronectin and collagen I is modulated by gangliosides in vitro. Cell Adhes. Commun. 1995, 3:27-43.
30. Hedberg K.M., Dellheden B., Wikstrand C.J., Fredman P. Monoclonal anti-GD3 antibodies selectively inhibit the proliferation of human malignant glioma cells in vitro. Glycoconjugate J. 2000, 17:717-726.
31. Oblinger J.L., Pearl D.K., Boardman C.L., Saqr H., Prior T.W., Scheithauer B.W., Jenkins R.B., Burger P.C., Yates A.J. Diagnostic and prognostic value of glycosyltransferase mRNA in glioblastoma multiforme patients. Neuropathol. Appl. Neurobiol. 2006, 32:410-418.
32. Watanabe R., Ohyama C., Aoki H., Takahashi T., Satoh M., Saito S., Hoshi S., Ishii A., Saito M., Arai Y. Ganglioside G(M3) overexpression induces apoptosis and reduces malignant potential in murine bladder cancer. Cancer Res. 2002, 62:3850-3854.
33. Uemura S., Kabayama K., Noguchi M., Igarashi Y., Inokuchi J. Sialylation and sulfation of lactosylceramide distinctly regulate anchorage-independent growth, apoptosis, and gene expression in 3LL Lewis lung carcinoma cells. Glycobiology 2003, 13:207-216.
34. Kilbey A., Terry A., Jenkins A., Borland G., Zhang Q., Wakelam M.J., Cameron E.R., Neil J.C. Runx regulation of sphingolipid metabolism and survival signaling. Cancer Res. 2010, 70:5860-5869.
35. Jensen B.V., Johansen J.S., Price P.A. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin. Cancer Res. 2003, 9:4423-4434.
36. Hogdall E.V., Johansen J.S., Kjaer S.K., Price P.A., Christensen L., Blaakaer J., Bock J.E., Glud E., Hogdall C.K. High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. Oncol. Rep. 2003, 10:1535-1538.
37. Cintin C., Johansen J.S., Christensen I.J., Price P.A., Sorensen S., Nielsen H.J. High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cancer 2002, 95:267-274.
38. Johansen J.S., Drivsholm L., Price P.A., Christensen I.J. High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer 2004, 46:333-340.
39. Tanwar M.K., Gilbert M.R., Holland E.C. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res. 2002, 62:4364-4368.
40. Pelloski C.E., Mahajan A., Maor M., Chang E.L., Woo S., Gilbert M., Colman H., Yang H., Ledoux A., Blair H., Passe S., Jenkins R.B., Aldape K.D. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin. Cancer Res. 2005, 11:3326-3334.
41. Ku B.M., Lee Y.K., Ryu J., Jeong J.Y., Choi J., Eun K.M., Shin H.Y., Kim D.G., Hwang E.M., Yoo J.C., Park J.Y., Roh G.S., Kim H.J., Cho G.J., Choi W.S., Paek S.H., Kang S.S. CHI3L1 (YKL-40) is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells. Int. J. Cancer 2011, 128:1316-1326.
42. Junker N., Johansen J.S., Hansen L.T., Lund E.L., Kristjansen P.E. Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Sci. 2005, 96:183-190.
43. Shao R., Hamel K., Petersen L., Cao Q.J., Arenas R.B., Bigelow C., Bentley B., Yan W. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 2009, 28:4456-4468.
44. Gronlund B., Hogdall E.V., Christensen I.J., Johansen J.S., Norgaard-Pedersen B., Engelholm S.A., Hogdall C. Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA 125). Int. J. Biol. Markers 2006, 21:141-148.
45. Schegg B., Hulsmeier A.J., Rutschmann C., Maag C., Hennet T. Core glycosylation of collagen is initiated by two beta(1-O)galactosyltransferases. Mol. Cell. Biol. 2009, 29:943-952.
46. Lu Y., Yi Y., Liu P., Wen W., James M., Wang D., You M. Common human cancer genes discovered by integrated gene-expression analysis. PLoS One 2007, 2:e1149.